Amgen Tells Sandoz On Enbrel: You Lost On The Facts
Sandoz Has Taken Etanercept Biosimilar Fight To US Supreme Court
Amgen has hit back at Sandoz’ petition for a writ of certiorari against a US Court of Appeals for the Federal Circuit decision that leaves the biosimilar sponsor unable to market its Enbrel biosimilar more than three decades after the biologic was first launched.
